Under the terms of the license agreement, Anesiva will receive an undisclosed up-front payment, along with milestone payments for certain key clinical and regulatory achievements, royalties on future sales, as well as royalties on revenues from any future sub-licensing of the technology by Particle Therapeutics.
About Anesiva's Drug Delivery Technology
Anesiva owns intellectual property covering the delivery of solid particles of proteins, peptides and small molecules (other than vaccines) into the skin at high velocity by pressurized gases. The technology aims to provide subcutaneous and systemic delivery of drugs without the pain and inconvenience associated with injections and needles. With Anesiva's drug delivery technology, patients may benefit from better control of their disease, reduced dosing schedules, and less pain compared to the administration of drugs with needles. Anesiva is utilizing this technology in its recently FDA-approved product Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, 0.5 mg., for the rapid needle-free local delivery of lidocaine to reduce pain associated with venous access procedures.
About Anesiva and its Diverse Portfolio of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to
be the leader in the development and commercialization of novel therapeutic
treatments for pain. The company has one approved product and one drug
candidate in development for multiple pain-related indications. On August
16, 2007, the FDA approved Anesiva's first product, Zingo. The second
product in the portfolio, Adlea(TM) (formerly 4975), has been shown to
reduce pain after only a single administration for weeks to months in
multiple settings in numerous mid-stage clinical trials for site-specific
|SOURCE Anesiva, Inc.|
Copyright©2007 PR Newswire.
All rights reserved